An interventional study of MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice in Microvascular Coronary Dysfunction, Microvascular Angina and Coronary Microvascular Dysfunction (CMD), sponsored by Royal United Hospitals Bath NHS Foundation Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Royal United Hospitals Bath NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Microvascular Angina with a site in United Kingdom — 6 open to participants now, 12 under way, none of them phase 3. Microvascular Angina · United Kingdom.
Among the 18 studies in Microvascular Angina with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 15th registered.
111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.
Browse Microvascular Angina studies →6 of the 18 studies in Microvascular Angina with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Leicester · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 16+
AngioInsight · Sites in United Kingdom, United States
Ages 18+
NHS National Waiting Times Centre Board · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 79 across 63 interventional studies indexed under Microvascular Angina.
Median enrollment 59 across the 12 interventional studies, 610 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Royal United Hospitals Bath NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Royal United Hospitals Bath NHS Foundation Trust has 1 study filed under Microvascular Angina — fewer than ten, so there is no comparison to draw.
3 of the studies in Microvascular Angina with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06070662University of LeicesterNon-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study | 2026-12 |
| NCT06681896Royal United Hospitals Bath NHS Foundation TrustMicrovascular Coronary Rehabilitation For Improving Treatment - Feasibility Study | 2027-04-01 |
| NCT06854302NHS National Waiting Times Centre BoardAngina After PCI: a Systems Medicine Study | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Microvascular Angina with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the feasibility of undertaking a randomized controlled trial assessing the impact of a personalised, intense cardiac rehabilitation programme involving high intensity interval exercise (HIIT) and dietary advice (termed MICROFIT) on symptom burden in patients with microvascular coronary dysfunction.
The main questions it aims to answer are:
Participants will be randomized to either MICROFIT + Usual Care, or Usual Care group.
Participants in both arms of the trial will:
Participants in the intervention arm of the study will:
Undergo MICROFIT intervention. MICROFIT includes a combination of exercise and diet management sessions over 24 weeks. It involves:
Participants in the Usual Care arm of the study will:
The investigators hypothesise that an intensified and personalised healthcare delivered lifestyle intervention (MICROFIT) will improve anginal symptoms in patients with microvascular coronary dysfunction. As a first step to a multi-centre randomised controlled trial (RCT) to establish efficacy, this feasibility study will test the components and acceptability of the intervention, alongside preliminary data on change in anginal symptoms to guide the powering of the subsequent RCT.
Participants:
The investigators aim to recruit 40 participants (men and women) with confirmed coronary microvascular dysfunction identified via existing clinical pathways (following an invasive coronary angiography study resulting in a diagnosis of microvascular angina) at two study sites, the Royal United Hospitals Bath NHS Foundation Trust (RUH) and University Hospitals Bristol and Weston NHS Foundation Trust(UHBW). Invasive coronary angiography with a microvascular study is a gold standard assessment for microvascular dysfunction nationwide and thus would be transferrable to all sites in the proposed subsequent multicentre randomised controlled trial.
A named cardiologist at each site who will be a member of the research team will undertake the screening. Potential participants will be approached on the day of their attendance for microvascular dysfunction testing following the procedure, once microvascular dysfunction has been confirmed (as per inclusion criteria), or during a routine follow up appointment as part of usual care relating to the diagnosis of coronary microvascular disease. Potential participants will be informed of the experimental protocol both verbally and in writing before providing informed consent. The study will be conducted in accordance with the Declaration of Helsinki. Participants will be block randomised 1:1 using a web-based platform (Sealed Envelope: https://www.sealedenvelope.com/). Participants will be randomised to either usual care (control arm) or MICROFIT with usual care, in permuted blocks of four and stratified for sex. The control arm contributes to a robust assessment of feasibility (e.g. consent and attrition rates) and a comparator for the preliminary data on anginal symptom burden change.
TRIAL ARMS:
Usual care (control arm):
All patients will be reviewed clinically by the Cardiologist performing the initial assessment. The cardiologist will address cardiovascular risk factors and prescribe any therapies, for example aspirin or statin therapy, as indicated by NICE guidelines. The Cardiologist will have over-arching responsibility for patients involved in the study, however, each patient's General Practitioner will be provided with a study information sheet and encouraged to adjust medications as needed according to national guidelines (e.g. for diabetic or hypertension management if these improve whilst participating in the study). The Cardiologist will also provide routine, verbal one-off lifestyle advice in line with NICE guidance, recommending 150 minutes of moderate exercise per week, encouraging a healthy, balanced diet, weight loss, reducing alcohol consumption and smoking cessation where necessary. The participants in the usual care arm will undergo the same assessments at baseline and at 24 weeks as the MICROFIT + Usual care arm, following which they will be offered a taster session with the personal trainer as well as information booklet regarding dietary advice offered to the participants in the MICROFIT + Usual Care arm.
MICROFIT + usual care (intervention arm):
MICROFIT is a lifestyle intervention designed to enable and support successful behavioural change with a predominant focus on exercise and diet. There is a focus on 1-on-1 delivery, higher intensity exercise, and updated dietary advice that aligns with the latest evidence-base for both microvascular dysfunction and broader cardiovascular disease. The programme will be explicitly introduced to each participant by the Cardiologist to ensure that the programme is presented as a meaningful intervention that can improve health outcomes. From the patient perspective, the Cardiologist will be seen as leading a multidisciplinary team, including exercise trainers and nutritional advisors, who are collectively working to improve the patient's microvascular function, measured both in terms of symptoms as well as objectively through stress perfusion MRI. The Cardiologist will introduce the concepts involved in the nutritional advice to the participant in the introductory session, provide advice and oversight to both the nutritional and exercise trainers throughout, and conduct further clinical reviews at the end of each intervention phase.
MICROFIT has three phases: (1) induction, (2) consolidation and (3) maintenance. Below the structure of different phases of MICROFIT trial delivery is summarised. The exercise and dietary components are further explained in the next section.
Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour exercise trainer supervised exercise sessions (described below), with once-weekly sessions of prescribed moderate-intensity "homework". Weekly body metrics (BP, HR, BMI) will enable goal-setting and feedback to encourage adherence.
Diet: Baseline 1-hour educational session with a dietician, followed by two 30 minute follow up sessions. These will be delivered virtually or face to face.
Phase 2 - Consolidation (10 weeks) Exercise: Reduced supervised session frequency to once-weekly, with two sessions of prescribed moderate-intensity homework/week. Body metrics 2-weekly.
Diet: 2x 30-minute "touch-base" sessions every 5 weeks, providing ongoing behavioural support of self-monitoring and goals.
Phase 3 - Maintenance (6 weeks) Exercise: Supervised sessions reduced to one every 3 weeks, with three times/week prescribed sessions of homework (now higher-intensity aerobic exercise). Body metrics assessed at penultimate visit.
Diet: A 30-minute "touch-base" session responding to changes in behaviour, where necessary.
Below each component of the MICROFIT intervention is explained.
Exercise Component:
(i)Supervised Sessions: Experienced exercise trainers will lead supervised 1:1 exercise sessions incorporating HIIT based on the Norwegian4x4 model for CAD patients. At the start of each supervised exercise session, participants will be asked about any change in symptoms or medications and have blood pressure and heart rate measured. Participants will be taught the Borg Rating of Perceived Exertion (RPE; 6-20). The acceptable maximal heart rate will be calculated upon patient's age baseline CPET results, adjusted as recommended for patients taking beta-blockers. The first session will consist of a graduated, lead-in of moderate intensity exercise prior to commencement of HIIT in subsequent sessions. Supervised sessions will use a cardiovascular exercise (e.g. static bike or treadmill) and HIIT sessions will comprise a 3-minute warm-up; four 4- minute high-intensity intervals at RPE 15 (hard), finishing at RPE 17-18 (very hard); 3 minutes of active recovery at RPE 11-13 (somewhat hard) between each interval; and conclude with 5-minute recovery as is advised for patients with cardiovascular disease. Trainers will help maintain target intensity and monitor participants throughout for concerning symptoms. To enable this and mitigate risk, all trainers will be required to complete a MICROFIT training course that will incorporate symptom supervision, basic life support and defibrillator training. All exercise facilities will have a defibrillator on site. In addition, given the benefits of resistance exercise, especially for blood pressure control, the sessions will conclude with twenty minutes of resistance training. The exercise trainer will feedback power data to participants as they work through the programme to highlight visible progress being achieved.
(ii) Homework Sessions: To enhance the weekly workload achieved and support long-term behaviour change, participants will be prescribed "homework" exercise sessions. This will comprise moderate-intensity aerobic exercise for 45-minutes in induction and consolidation phases (e.g., brisk walking), and increase to higher-intensity exercise (e.g., hill walking or jogging) in the maintenance phase. A once weekly resistance exercise session using workouts learnt in the supervised session during phases 1 and 2 will be added in phase 3. Participants will be provided with written guidance on effort levels, how to monitor their symptoms, and a HR monitor (MyZone) to support self-directed exercise intensity, ensuring their intensity is at the appropriate level. These data will be reviewed at supervised exercise sessions by personal trainers to evaluate progress and provide support and kept for subsequent analysis.
Dietary Component:
Patients will complete pre-session combined photographic/written diet diaries (retained by the research team for dietary analysis). Recognising that there is no "one-size-fits-all" pattern, the nutritional advisor will work with the patient to identify residual barriers to dietary change and potential solutions. The photographic diet diary will help highlight incremental areas for improvement in a straightforward manner. Where indicated, the dietician will also continue to highlight the importance of smoking cessation during sessions. The principles and guiding framework for the dietary advice will be:
TRIAL ASSESSMENTS:
The trial comprises of five assessment episodes:
Participants in the intervention arm will undertake assessments 1-5, whereas participants in the usual care arm will attend assessments 1 and 4 only.
Assessments 1 and 4 will require attendance at RUH or UHBW (depending on participant's recruiting hospital), University of Bath and St Joseph's Hospital, Newport. Assessments 2 and 3 will require attendance at RUH or UHBW only. Assessment 5 will be undertaken face to face or virtually according to participant preference.
In order to minimise travel and appointment burden for patients, part of baseline assessment 1 will take place at the same time as screening visit. During this visit some of the baseline clinical investigations will be undertaken (including blood tests (HbA1c, lipid profile, inflammatory markers),ECG, echocardiography (if not performed within last 6 months), body anthropometrics (height, weight, waist and hip circumference), clinic BP measurement and patient questionnaires (Seattle Angina Questionnaire, Hospital Anxiety and Depression Scale and EuroQol-5D-5L questionnaire for quality of life). The patients will also be issued blood pressure monitor for 7-day home BP monitoring and wearable activity device (GeneACTIV), alongside instructions for diet diary to be undertaken at home. The participant will also be made an appointment to attend Cardiac MRI at St Joseph's Hospital and CPET (cardiopulmonary exercise test to assess fitness levels) and body composition testing (DEXA) at University of Bath. This concludes baseline Assessment 1. Assessment 4, concluding the trial, will follow the same structure.
Assessments 2 and 3 will take place solely with participants in the intervention arm of the trial. These visits will take place at RUH or UHBW and will comprise clinical review, blood tests, body anthropometrics and clinic BP.
Assessment 5 will take place face to face or virtually and will comprise of a qualitative interview on participant experience in the trial. All 20 intervention participants will be invited for a 30 - 40-minute interview upon completion to capture all ranges of experiences of participation in the trial. Interviews will seek feedback on trial participation, including barriers and facilitators to trial procedures, exercise adherence, and explore any unanticipated effects of taking part. Encrypted interviews will be recorded, transcribed verbatim and analysed using both narrative and thematic analysis.
In-depth (30 - 40 minute) interviews will be conducted with all practitioners involved in delivering MICROFIT to identify areas that need to be adapted or changed to implement the intervention in a future trial (or rollout). Specifically, this will include their experience of delivering and supporting MICROFIT, the quality of the training resources, and how participation affected their other work and relationships with patients.
MICROFIT adherence measurement:
Adherence to MICROFIT will comprise of attendance at supervised exercise and nutritional sessions, and participation in home unsupervised sessions.
A summary of the assessments at each time points is shown in Trial Flowchart within trial Protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MICROFIT intervention will be delivered in addition to Usual Care arm clinical review and advice. MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.
Other: MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice
All patients will be reviewed clinically by a cardiologist. They will address cardiovascular risk factors and prescribe any therapies as indicated by current medical guidelines, for example statin or ACE inhibitors. The Cardiologist will also provide routine, verbal one-off lifestyle advice in line with NICE guidance, recommending 150 minutes of moderate exercise per week, encouraging a healthy, balanced diet, weight loss, reducing alcohol consumption and smoking cessation where necessary.
MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet. Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week. Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions. Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week. Diet: 30-minute sessions every 5 weeks. Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week. Diet: one final 30 minute session after week 3.
Establish recruitment rate
A key feasibility outcome for a potential future randomised controlled trial will be to establish recruitment rates: defined as the proportion of eligible patients who accept the invitation to participate in the study.
Time frame: Week 0
Establish retention rate
A key feasibility outcome for a potential future randomised controlled trial will be to examine retention: defined as the proportion of recruited participants who complete the study.
Time frame: Week 24
Establish adherence
A key feasibility outcome for a potential future randomised controlled trial will be to examine adherence: defined as, for participants in the intervention arm, the proportion of offered sessions completed.
Time frame: Week 24
Assess acceptability of the intervention
A key feasibility outcome for a potential future randomised controlled trial will be to examine the acceptability of the intervention (MICROFIT) to participants and clinicians. This will be assessed qualitatively by an end of study interview.
Time frame: Week 24
Assess acceptability of the study design
A key feasibility outcome for a potential future randomised controlled trial will be to examine the acceptability of the study design. This will be assessed qualitatively by an end of study interview.
Time frame: Week 24
Change in anginal symptom burden
Data on anginal symptom burden as measured by the 7-item Seattle Angina Questionnaire (SAQ-7) \[0-100, 0=worst health, 100=full health\] will be collected to guide power calculations for large scale RCT in the future, where it would be the primary outcome.
Time frame: Week 24
Change in myocardial perfusion with quantitative stress MRI
An assessment of change in myocardial perfusion reserve \[ratio of myocardial blood flow at hyperaemia/myocardial blood flow at rest\] utilising quantitative stress perfusion cardiac MRI.
Time frame: Week 24
Change in myocardial oxygenation
Qualitative and quantitative assessment of change in myocardial oxygenation utilising Oxygenation-Sensitive Cardiac MRI
Time frame: 24 weeks
Change in cardiorespiratory fitness
Serial cardiopulmonary exercise tests will provide a measurement of maximum rate of oxygen consumption attainable during physical exertion (VO2 peak), reported in mL/kg/min.
Time frame: 24 weeks
Change in blood pressure control
Participants will undertake 7-day blood pressure monitoring at home, the results of which will be averaged \[mmHg\]
Time frame: 24 weeks
Change in body fat composition
Changes in body fat composition will be assessed with dual-energy X-ray absorptiometry (DEXA).
Time frame: 24 weeks
Change in body anthropometrics (Body Mass Index - BMI)
Change in body mass index (BMI) will be reported using aggregated height (metres) and weight (kilograms) to arrive at one reported value (kg/m\^2).
Time frame: 24 weeks
Change in anthropometrics - waist circumference
Change in abdominal waist circumference (centimetres) will be reported.
Time frame: 24 weeks
Change in glucose control, measured with the glycated haemoglobin test (HbA1c)
Serial blood sampling for HbA1c (mmol/mol)
Time frame: 24 weeks
Change in serum lipid levels
Serial blood samples will be taken to assess serum lipid profile (total cholesterol, \[mmol/L\], LDL cholesterol \[mmol/L\], HDL cholesterol \[mmol/L\], triglycerides \[mmol/L\])
Time frame: 24 weeks
Change in serum inflammatory markers
Serial blood testing to assess C-reactive protein (CRP) (mg/L)
Time frame: 24 weeks
Change in left ventricular ejection fraction, measured on echocardiography
An assessment of cardiac systolic function, defined by left ventricular ejection fraction, will be performed using echocardiography.
Time frame: 24 weeks
Change in left ventricular strain assessed on echocardiography
An assessment of cardiac systolic function, defined by left ventricular strain, will be performed using echocardiography.
Time frame: 24 weeks
Change in left ventricular filling pressure measured on echocardiography
An assessment of cardiac diastolic function, with echocardiography measure of left ventricular filling pressure.
Time frame: 24 wees
Change in left atrial strain, measured on echocardiography
An assessment of left atrial strain, a marker of diastolic dysfunction, will be performed using echocardiography.
Time frame: 24 weeks
Change in self-perceived mental health, assessed with the Hospital Anxiety and Depression Scale (HADS)
Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 with higher scores reflecting a higher degree of anxiety and/or depression.
Time frame: 24 weeks
Change in patient reported health-related quality-of-life, measured with the EuroQol Group (EuroQol) EQ-5D-5L questionnaire
Patient reported health-related quality-of-life will be recorded using the EuroQol EQ-5D-5L questionnaire.
Time frame: 24 weeks
Evaluate data collection procedures
To confirm that all data collection procedures (clinical, intervention and health economic data points) are achievable. This will be assessed as a percentage of the total number data-points we attempt to collect.
Time frame: Week 24
Plan to share: Yes — All IPD collected as part of trial
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: Beginning 1 month after publication of results and ending 5 years after
Access criteria: Requests for data sharing will be reviewed on an individual basis upon request to the research team.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 28 months after the start.
Of 24 interventional studies with no phase under Microvascular Angina, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 66. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal United Hospitals Bath NHS Foundation Trust